USP11 and prostate carcinoma: Mitoxantrone, originally developed and approved as a cytotoxic anthracenedione antineoplastic agent for the treatment of acute myeloid leukemia, prostate cancer, and breast cancer, was reported to inhibit the activity of USP11 (41).